Fallouh Healthcare, is a Medical Device start-up company developing a medical device used for monitoring patients following cardiac surgery. The business is concentrating on finding a solution to a serious issue brought on by postoperative cardiac tamponade. Although cardiac surgery is largely safe, some patients develop a life-threatening condition called cardiac tamponade in the immediate postoperative period. Cardiac tamponade is caused by the collection of blood clots in the pericardial space compressing the heart and compromising the cardiac output. The diagnosis of tamponade is subjective, difficult, typically happens late at night and can be confused with other causes of heart …

58 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

With the help of medical technology solutions and innovation we want to save as many heart failure patients as possible. About Scandinavian Real Heart AB – Only around 8,000 heart transplants take place annually worldwide and the availability of donated hearts is very limited. The need is great and patients with heart failure die waiting for a new heart. Scandinavian Real Heart AB is developing a heart pump (TAH) that mimics the body's natural circulation and that can be used as a transitional solution for patients waiting for a heart transplant. Successful studies have been carried out on anesthetized animals …

69 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Our mission is to save lives by making every organ count Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver …

55 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Driven by the heart We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Secretome is a clinical-stage company focused on orphan and underserved cardiac diseases Secretome Therapeutics is a clinical-stage cell therapy company focused on orphan and underserved cardiac diseases. STM-01, the lead drug, is a neonatal cardiac progenitor cell (nCPC) isolated from cardiac tissue excised during life-saving, open-heart surgery on newborns with congenital heart defects. The main target indication for STM-01 is Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM).

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

CorWave develops and manufactures innovative implantable blood pumps based on a breakthrough membrane technology. CorWave is a French company developing innovative cardiac assist devices. CorWave’s wave membrane pump is a breakthrough technology that differs from today’s commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave’s membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up …

59 similar entities Tags: FrenchTech120 Type: Startup Activities: deeptech healthtech manufacturing nanotech Technologies: Synthetic Biology

A Healthier Life With Every Beat FineHeart is a clinical stage medical device company based in Bordeaux, France. Its innovative product, FLOWMAKER®, has the potential to treat 200,000 patients with advanced heart failure each year. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US$5 billion. FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The …

87 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Off-the-shelf precision vaccines to prevent deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

HVR Cardio is a medical device company focused on developing first-generation transcatheter mitral valve repair solutions. Our minimally invasive technology has the potential to enable safer, faster, and less traumatic cardiac interventions for mitral regurgitation patients worldwide. HVR Cardio’s innovative HELIX ring technology has been carefully designed to fit the anatomy of the mitral valve. This allows fast and easy implantation and most importantly, restoration of the valve geometry leading to uncompromised clinical efficacy. With our catheter-based product, we expect to reduce the invasiveness, operation time, and morbidity associated with mitral valve repair operations. This would allow effective treatment of …

60 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Imaging life, protecting lives. Aurum Biosciences Ltd is a clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, oncology, inflammatory conditions, spinal cord injury, and dementia. Preclinical development has been completed in the lead indication (AIS) and approval has been granted to initiate clinical studies in acute stroke patients. Concurrently, Aurum is pursuing opportunities to develop its pipeline indications with a focus on inflammatory conditions and oncology.

72 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and …

402 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market. The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the …

77 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Keep track of the heart. Everywhere. All the time. Vectorious Medical Technologies develops novel treatment for heart failure patients which is based on physician directed, patients’ self-management paradigm. Leveraging its advanced, first of its kind, implantable V-LAP platform, which harvests valuable information from the heart’s left atrium, physicians and patients can monitor and manage disease status, prevent hospitalizations and improve quality of life. The V-LAP system is an investigational device which is currently under evaluation in multiple clinical studies in Europe, Israel and the U.S. Medical Devices, Wireless communication, Miniature Implants, Heart Failure, Remote Monitoring, and Sensors

137 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Repairing the human powerplant: mitochondrial recycling therapy ANKIAL Pharma is a biotech-Pharma start-up company that is developing a drug to treat hypertrophic cardiomyopathy (HCM), a heart disease that affects 20 million patients worldwide. The drug ANK0121 (patented by INSERM/Bordeaux Hospital and University) acts on mitochondria, the powerplant of the heart. This technology promotes mitochondrial recycling to improve heart bioenergetics and prevent hypertrophic cardiomyopathy in various in vivo models of HCM. ANKIAL operates from the preclinical phase to the marketing authorization. The team includes 5 founders. The CEO Bruno LEGRAND has 25 years of expertise in the pharmaceutical industry sector (cardio-metabolic …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Elevating Cardiovascular Interventional Imaging with Proprietary Hyper-Augmentation Technologies Metacognitia: pioneering the future of cardio-vascular imaging with advanced Hyper-Augmentation technology. Metacognitia is at the vanguard of MedTech innovation, introducing a groundbreaking hybrid of AI & BioPhysics technology tailored to redefine cardio-vascular imaging, driving to a new era with our advanced Hyper-Augmentation technology. Our innovations offer: ▶ Sharper diagnostics: elevating precision to new heights, providing crystal-clear insights into heart health. ▶ Predictive forecasts: empowering proactive care with accurate, early prognosis capabilities. ▶ Optimized interventional support: ensuring fine-tuned strategies for interventional procedures such as Optimal Stenting. Committed to safety and efficiency, our technology …

128 similar entities Type: Startup Activities: deeptech healthtech Technologies: A.I.

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Liquid Ventilation for Life Orixha's mission is to save the patients's lifes in critical care through liquid ventilation. Orixha is developing the Vent2Cool medical device to almost immediately protect the vital organs, in particular the brain and heart, of patients resuscitated after cardiac arrest and thus significantly reduce mortality and morbidity. Vent2Cool turns the lungs into a heat exchanger with the blood compartment. This makes it possible to induce ultra-rapid therapeutic hypothermia in minutes where current hypothermia solutions take hours to reach the target temperature of 33°C.

62 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Listen early to act effectively SentinHealth was a MedTech/AI company specialized in innovative integrated care solutions for monitoring and preventing exacerbations of Heart Failure. We were driven by the unmet need of severe patients requiring automatic monitoring for their life-time. Headquartered in Paris - Research Lab in Grenoble Alps Heart Failure

132 similar entities Type: Startup Activities: deeptech healthtech Technologies: A.I. IoT

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tarian Pharma's mission is to develop new drugs that ensure optimized cancer treatment by protecting cancer patients from side effects that would lead to dose reductions or discontinuation. This approach is designed to increase patients' chances of recovery and survival. Tarian Pharma was created by two dermatologists and a pharmacist, with more than 75 years of experience in the pharmaceutical industry and having been actively involved in the development and marketing of more than 15 new drugs in Europe, the United States and Asia.

107 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pledged to save millions At SMT (Sahajanand Medical Technologies), we are revolutionizing healthcare through innovation and clinical excellence. As a multinational MedTech company with diversified manufacturing facilities and operations across multiple countries, SMT is at the forefront of high-end cardiovascular, endovascular, and structural heart devices. Guided by our mission, “Pledged to Save Millions,” we specialize in developing clinically proven solutions for coronary interventions, occluders for congenital defects, and structural heart therapies. Our products undergo rigorous clinical trials and are featured in world-class medical journals like The Lancet, New England Journal of Medicine, BMJ Open, and JACC, cementing our position as …

159 similar entities Type: SMB Activities: manufacturing deeptech healthtech Technologies: Synthetic Biology

Finding cures for cardiovascular disease through world-class medical research. The Victor Chang Cardiac Research Institute is dedicated to finding cures for cardiovascular disease through world-class medical research. Renowned for the quality of its scientific breakthroughs, the team at the Institute is working urgently to discover better ways of diagnosing, treating and preventing the onset of heart disease. With over 200 scientists and doctors working together across 23 laboratories in NSW and WA, the Victor Chang Cardiac Research Institute has earned its place on the global stage as one of the most respected medical research facilities in the world. The Institute …

57 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Healing Hearts Repairon is an innovative clinical-stage biotech company in Göttingen (Lower Saxony, Germany), developing stem cell-based heart muscle tissue for the treatment of advanced heart failure. The goal is to improve the cardiac function of our seriously ill heart patients so that they can lead a normal life again.

84 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Fighting chronic and fatal diseases Tirecat Health is a company developing a family of novel polymers with amazing potential in the healthcare field. We are propelled with purpose to fight chronic and fatal diseases affecting patients worldwide using our revolutionary technology to improve their quality of life. In order to make this purpose a reality, the company is preparing to move towards the clinical phase to demonstrate the astonishing results seen in preclinical trials.

300 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the …

119 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

225 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pionnier de la thérapie régénératrice cardiaque CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans. Heart Regeneration

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sky Medical develops bioelectronic devices to treat a wide range of acute and chronic circulatory conditions. Sky Medical develops bioelectronic devices integrated with OnPulse neuromodulation technology to prevent and treat a wide range of acute and chronic circulatory conditions (e.g. to prevent venous thromboembolism (VTE), to prevention and reduction of edema after surgery, to heal venous and arterial leg ulcers as well as chronic wounds, and speed-up recovery time for high-performance athletes. After conducting further clinical research, OnPulse is now being used in hospitals and in community care centers to accelerate patient recovery after surgery and to accelerate healing of …

189 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company’s lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. The company has raised over USD 40 million to date. …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation. Applied. Founded in 2021, POLYGON Therapeutics is a Paris-based biotechnology company developing precision cardio-immunology therapies targeting inflammatory drivers of cardiovascular disease. The company combines translational human biology, biomarker-driven development and immunology expertise to develop novel therapeutic approaches in cardiovascular disease.

228 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Their life. Your skills. Our technology. CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic …

89 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Using cryotherapy to stabilize vulnerable plaque and reduce the risk of heart attack CryoTherapeutics has developed a novel, minimally invasive, catheter-based cryotherapy system (CTS) engineered to address an unmet need in cardiology: the treatment of coronary vulnerable plaque (VP), a leading cause of myocardial infarction (MI), that often leads to fatal events. CryoTherapeutics’ technology is designed to deliver localized cryotherapy to vulnerable plaques, cooling the plaques to temperatures between -10 to -20° C. The cryotherapy aims to stabilize the vulnerable plaques by reducing inflammation and increasing the fibrous cap thickness, hence lowering the risk of rupture and preventing future MI. …

123 similar entities Type: SMB Activities: deeptech biotech Technologies: New Materials

Full Cerebral Embolic Protection System to Reduce the Risk of Cerebrovascular Events during TAVR/ TAVI. Protembis is an Aachen, Germany based medical device startup. It develops a novel catheter-based filter device for use during cardiac interventions. The device is designed to minimize the risk of stroke and other neurological injury during these interventions – particularly during transcatheter aortic valve replacement procedures (TAVR/ TAVI). The filter blocks embolic debris from entering the blood vessels leading to the brain. The initial safety and feasibility of the ProtEmbo® device has been demonstrated in a first-in-human study in 2017/ 2018. The imaging data of …

70 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

234 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

3-D Matrix is a medical device company that offers innovative peptide technology, revolutionising the way healthcare professionals manage oozing bleeding during surgery. Join our community of healthcare professionals: https://www.linkedin.com/groups/12920054/ Headquartered in Tokyo, Japan, 3-D Matrix has expanded across America, Europe, Middle East and Asia. The company collaborates with many researchers, surgeons, healthcare providers and distributors across the world to continually improve on our product. We keep patient outcome at our heart, operating on three main principles: agility, proactiveness and focus. Follow us on Twitter @3dm_emea Sign up to our newsletter for the latest clinical data and product announcements: https://news.3dmatrix.com/newsletter-subscription Medical …

443 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Bridge-to-recovery by design Systol Dynamics designs and develops an innovative Ventricular Assist Device (VAD) that extends the benefits of mechanical circulatory support to less severe heart failure patients. Uniquely positioned in the aorta by transcatheter implantation, the Systol Dynamics’s VAD is at one minimally-invasive, connected and removable. Unlike terminal solutions, bridge to transplant or destination therapy, it relieves the patient’s heart and enables physiological recovery, ultimately leading to cardiac pump removal. Founded in 2018 by a cardiologist with more than 30 years of experience in the management of cardiac insufficiency, Systol Dynamics is managed by a team of experts in …

59 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Transformative vascular implants. Addressing major life-threatening diseases, backed by Nobel-winning science. Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

95 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

We’re EnovisTM – a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We strive to make each day better by partnering with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. We do this through our extraordinary talent, a laser focus on innovation, strategic acquisitions, and a common culture of continuous improvement. With more than 7,000 incredible employees worldwide and an extensive range of products, services, and integrated technologies …

232 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

337 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Facing the global challenge of the lack of heart grafts, PROCOPE Medicals develops an innovative total artificial heart Thousands of people die every year of severe heart failure, due to the lack of donors, heart transplant is increasingly rare : 3% of patients receive a donor heart. PROCOPE Medicals acts and develops a new generation of artificial heart.

59 similar entities Type: Startup Activities: healthtech deeptech

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Next-Generation Stroke Treatments 👉Funding round is still open: https://capitalcell.com/campaign/freeox/ FreeOx Biotech: Advancing Stroke Care through Innovation and Precision Medicine FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming acute ischemic stroke (AIS) management. Our mission is to improve outcomes for stroke patients through the discovery and development of Cerebrovascular Protective Therapeutics. Our lead asset, Ox-01, is a Phase 3-ready investigational drug with breakthrough potential as an emergency adjunct therapy to Mechanical Thrombectomy. Selected by the prestigious StrokeNet Thrombectomy Endovascular Platform (STEP) program, funded by the National Institute of Neurological Disorders and Stroke (NINDS), Ox-01 represents a …

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Developing first-in-class CD31xITAM bispecific antibodies for targeted immune modulation Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases. The company’s lead program is a first-in-class CD31×GPVI bispecific antibody being developed for the treatment of thromboinflammatory diseases. This novel approach provides both antithrombotic and anti-inflammatory efficacy while minimizing bleeding risk, thereby addressing major critical medical unmet needs in the field. Our company is financed by leading European investors and led by an experienced management team. Santé, Healthcare, …

203 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlock cells. Deliver innovation. PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies using our intracellular drug delivery shuttle. Our technology platform enables us to address the previously undruggable intracellular space with multiple payloads such as peptides, proteins, antibodies, and nucleic acids. As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

SignaCor is a clinical stage, drug development company, dedicated to the treatment of cardiac disease. SignaCor is a clinical stage, drug development company, spun-out from Queen’s University Belfast, dedicated to the treatment of cardiac disease. At SignaCor, we are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)—one that goes beyond symptom management to target the underlying disease pathology. Cardiaza is the first and only treatment that harnesses DNA methylation to address multiple underlying causes of symptomatic HCM, including established fibrosis, a key driver of disease progression.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Opening a new frontier in the fight against atherosclerosis PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will …

88 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Boosting the body's ability to defend against the damage of aging Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ultrasound Guidance during Radio Ablation Treatment of Cardiac Arrhythmias EBAMed (External Beam Ablation Medical) has developed an Ultrasound Imaging Solution to enable non-invasive treatment of Cardiac Arrhythmias. CardioKit is a dedicated cardiorespiratory gating platform developed specifically for cardiac radioablation. It integrates real-time ECG and ultrasound signals with AI-driven cardiac motion tracking to synchronize radiation delivery with the continuously moving cardiac target. When combined with a photon or proton therapy, CardioKit enables precise dose delivery to arrhythmogenic substrates while minimizing exposure to healthy myocardium and surrounding organs.

58 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Empowering Muscle Empowering Lives Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Heart Failure and Hypertrophic Cardiomyopathy

68 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation hemoperfusion devices to treat sepsis and multiple organ failure syndrome. Company's flagship product, Efferon LPS single-use hemoperfusion device is granted CE mark approval under EU MDR. Clinically validated approach, over 10.000 treated critical patients. Founded in 2016 to translate the most advanced polymeric adsorbent technology into routine clinical practice and to fight morbid diseases.

Type: Startup Activities: deeptech healthtech

Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

263 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The objective of Quantum Genomics is to become a leading actor in the treatment of cardio-vascular diseases through the development of a new therapeutic class: BAPAIs for BrainAminopeptidase A Inhibitors. We wish to develop and provide effective and well tolerated therapeutic treatments for controlling high blood pressure and to for preventing related cardio-vascular risks such as heart failure. High blood pressure remains a major public health concern. Quantum Genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the inhibition of brain Aminopeptidase A. The mid-term strategic objective of the company is to …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing transformative solutions for patients with infectious diseases and other difficult to treat conditions Positive Outcomes. Positive Patient Stories®. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that …

71 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Creating biologicals without refrigeration. Our patented novel Ensilication technology uses silica to create an individually tailored protective nanoshell around vaccines, antibodies and enzymes to prevent degradation, which can lead to spoilage. Once applied, the material can be stored and transported without the need for cold chain infrastructure, improving global access to medicines and reducing wastage and emissions across the pharmaceutical supply chain. Ensilication preserves the integrity of a wide variety of biomolecules and proteins, not only protecting against environmental degradation, but also making possible the development of more convenient administration such as subcutaneous and oral delivery for both humans and …

93 similar entities Type: Startup Activities: deeptech transporttech Technologies: Synthetic Biology

Combining ultrasound and optical imaging to revolutionize coronary revascularization PROBLEM Insufficient treatment of vulnerable plaque in the coronary arteries lead to costly and health impairing re-catheterizations In 2015, Coronary Artery Disease (CAD) affected 110 million people and resulted in 8.9 million deaths worldwide. CAD occurs when the arteries that supply the heart muscle with blood become hardened and narrowed, due to the buildup of cholesterol and plaque on their inner walls. Current treatment: To open the blocked coronary arteries, 80% of the patients are treated using a Percutaneous Coronary Intervention (PCI). - Of those patients treated with PCI, 12% get …

61 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Harnessing the healing potential of adenosine for tissue regeneration Privately held company focused on developing and marketing first-in-class regenerative therapies for osteoarthritis. Our proprietary platform technology harnesses the healing potential of the purinergic system which plays a critical role in maintaining cartilage homeostasis. Our lead product is a proprietary formulation for regenerating cartilage in joints with established osteoarthritis, targeting a rapidly growing joint preservation market. Our goal is to offer patients a disease modifying therapy with uncompromising efficacy relative to existing technologies. By developing this disease modifying therapy, we will significantly improve clinical outcomes and patient quality of life, and …

87 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

CardioScale is an Israeli medical device start-up founded 2012, pursuing a novel patent applied diagnostic for early detection of cardiovascular deterioration in various patients of heart failure and shock.

139 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Developing novel medications for patients with atrial fibrillation InCarda Therapeutics is a privately held biotechnology company backed by leading VC investors, Deerfield Management and HealthCap, developing novel drugs for the treatment of patients with atrial fibrillation (“AF”). Our mission is to enable rapid restoration of normal sinus rhythm ("NSR") with therapies designed to be fast-acting, safe, simple to use, and available across the continuum of care—from hospital-based cardioversion to at-home, self-administered treatment. Cardiovascular, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Clinical Research, Pre-Clinical Research, atrial fibrillation, and arrhythmias

127 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Excellence for Life BIOTRONIK is a global medical device company providing products and services for the treatment of cardiovascular and endovascular diseases. Patient well-being is our main priority. For 60 years, we have been driven by the desire to save lives and improve the quality of life of patients. With thousands of employees in more than 100 countries, we are among the world's leading medical technology innovators in the areas of cardiac rhythm management, electrophysiology and vascular intervention. Our technology empowers doctors around the world to provide their patients with the best possible healthcare. Heart rate management Implantable devices help …

140 similar entities Type: SMB Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Delivering Hope to the Heart of our Patients AuriGen Medical are an EUeic supported medical device start up, developing the next generation in left atrial appendage implant technology for the treatment of medication resistant longstanding persistent atrial fibrillation. #EUeic #eicAccelerator

93 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Nonclinical expert in cardiovascular pharmacology & electrophysiology and vascular functions PhysioStim is a French preclinical CRO dedicated to cardiovascular pharmacology and electrophysiology from discovery stages to clinical development. Whatever the therapeutic areas, we ensure robust and valuable preclinical data on cardiac and vascular activities and secondary pharmacology to secure in-vivo development and bring new safe therapies to patients. Thanks to our predictive and translational models, we define the POC of drug discovery, we investigate secondary pharmacology with on and off-target liabilities, and we address the safety purpose to build and support your IND submission (with mandatory and not mandatory assays). …

123 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

TRANSFORMING CARDIAC DRUG DISCOVERY HeartBeat.bio is a pioneering TechBio company leveraging a next-generation drug discovery platform to develop breakthrough medicines for heart failure patients. Heart failure is a rapidly growing global health crisis, affecting over 30 million people in major pharmaceutical markets, with limited treatment options. Despite its prevalence, innovation in this space has lagged—creating a massive opportunity for disruption. Our proprietary Cardioid Drug Discovery Platform integrates iPSC-derived cardiac organoids with AI-driven analytics and advanced automation. Unlike traditional drug discovery, which relies heavily on animal models with poor clinical translatability, our human-centric approach enables more predictive, efficient, and cost-effective drug …

76 similar entities Type: Startup Activities: deeptech Technologies: SaaS Synthetic Biology

Pioneering cellular rejuvenation using epigenetic restoration to reverse diseases of aging At Life Biosciences, we are on a mission to reverse age-related diseases. Our platform, termed epigenetic restoration, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect. It has the potential to rejuvenate cells and restore function in many age-related diseases. We are the sole company with intellectual property covering the therapeutic use of our epigenetic restoration technology. We are also the only company to have received FDA approval to advance this technology into human clinical studies. While our initial clinical trial is for optic neuropathies, …

93 similar entities Type: Startup Activities: biotech deeptech silvertech Technologies: Synthetic Biology

Cardiac Microcurrent C-MIC - A novel therapy for chronic heart failure Berlin Heals is a Start-up-Company in Berlin, Germany. We are devoted to the treatment of heart failure. We will redefine heart failure treatment with a novel device that is capable of healing the heart. Contact us at info@berlinheals.de to get in touch with us. Get more Information here: www.berlinheals.de R+D and Marketing of a novel cardiovascular device

67 similar entities Type: Startup Activities: deeptech healthtech biotech

Formerly named BioSig Technologies Inc. Streamex is a Real World Asset (“RWA”) tokenization company with Institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc. BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first of its kind combination of hardware and software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals’ and ‘reading between the lines.’ Our platform …

77 similar entities Type: Startup Activities: healthtech deeptech Technologies: IoT

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering Stroke Solutions ENGINEERING Stroke Solutions Acandis, founded in 2006, is a privately held German medical device company focused on the prevention and treatment of stroke. We have a passion for technology and our engineers are enthusiastic about creating solutions for unmet clinical needs to improve patient’s lives. We strive towards a comprehensive device portfolio and continuous development of products and services to improve stroke care for neurointerventionalists around the globe. The safety of our products has been demonstrated on the bench top and now the efficacy of those products is being proven in clinical trials. As a company we …

296 similar entities Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMPTM and CardiALLOTM therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's HelixTM transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

72 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. Our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function. We sought to restore healthy blood flow patterns by creating the world’s first biomimetic TAVR valve, …

61 similar entities Type: SMB Activities: healthtech deeptech

NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases. This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia …

185 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology